Why the study?
There was a need to establish basic recommendations for prevention and management of cardiotoxicity in breast cancer patients to ensure optimal cardiovascular care.
This consensus statement provides regional recommendations for the prevention, screening, and management of cardiotoxicity in breast cancer patients undergoing treatment with anthracyclines and trastuzumab.
Supports risk-stratified cardio-oncology monitoring during breast cancer therapy; extends prior consensus with actionable regional guidance.
This Galician consensus statement is a joint oncologists/cardiologists initiative indented to establish basic recommendations on how to prevent and to manage the cardiotoxicity in breast cancer with the aim of ensuring an optimal cardiovascular care of these patients. A clinical screening of the patients before treatment is recommended to stratify them into a determined risk group based on their intrinsic cardiovascular risk factors and those extrinsic arose from breast cancer therapy, thereby providing individualized preventive and monitoring measures. Suitable initial and ongoing assessments for patients with low and moderate/high risk and planned treatment with anthracyclines and trastuzumab are given; also, measures aimed at preventing and correcting any modifiable risk factor are pointed out .
No takes yet. Share an insight, caveat, or question.
Cueva et al. (2017) conducted a review in Breast cancer cardiotoxicity. Cardiotoxicity management and prevention guidelines was evaluated. Clinical screening and individualized monitoring based on intrinsic and extrinsic cardiovascular risk factors are recommended to prevent and manage cardiotoxicity in breast cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: